On August 26, 2026, the U.S. Food and Drug Administration approved Daraxonrasib, marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy or who are not candidates for multiagent therapy. It is the first targeted therapy of its kind approved for the most common form of pancreatic cancer, and it arrived roughly six and a half months ahead of the FDA’s own goal date.
For a disease that has seen far too few meaningful treatment advances, this is a genuine milestone. It is also a reminder of why the work of early detection cannot wait.
What the approval means
Daraxonrasib is a once-daily oral tablet that targets RAS, a protein that drives tumor growth in the large majority of pancreatic cancer cases. For decades, RAS and its most common mutated form, KRAS, were widely considered nearly impossible to target with a drug. That is what makes this approval scientifically significant, not just clinically.
The approval was based on RASolute 302, a randomized international Phase 3 trial that enrolled 500 patients with metastatic pancreatic adenocarcinoma whose disease had progressed after one prior line of therapy. Patients received either Daraxonrasib or the chemotherapy regimen of their physician’s choice. The results, as reported by the FDA:
- Median overall survival was 13.2 months for patients on Daraxonrasib, compared with 6.7 months for those on standard chemotherapy
- Median progression-free survival was 7.2 months, compared with 3.6 months
- The overall response rate was 30%, compared with 11%
Nearly doubling median survival in advanced pancreatic cancer is a result the field has been waiting a very long time to see. As with any cancer therapy, Daraxonrasib carries risks and side effects, and treatment decisions belong between patients and their care teams. But the progress is clear and additional trials are already underway to study the drug earlier in the course of the disease.
The part of the picture this approval does not change
Read the approval language closely and you find the limitation that defines this disease. Daraxonrasib is approved for patients with metastatic pancreatic cancer, meaning cancer that has already spread beyond the pancreas, who have already been through at least one round of treatment.
That is where most pancreatic cancer patients find themselves, because most pancreatic cancer is not caught until it has already spread. The disease produces few clear symptoms in its early stages, and there is no routine screening test offered to the general population the way there is for breast, colon, or cervical cancer. By the time a diagnosis arrives, the window for surgery, still the only potentially curative option, has usually closed.
That is why the overall five-year survival rate for pancreatic cancer sits at 13%. When the disease is found at its earliest stage, the five-year survival rate is 81%, more than six times higher.
A better second-line treatment extends life for patients who are already in a very difficult position. What it cannot do is put them back in the position where a cure was possible. Only earlier detection can do that.
“Even the most promising treatments face a much harder challenge once pancreatic cancer has spread. Our greatest opportunity to change outcomes is to pair better treatments with the ability to find the disease earlier, when patients have more options and potentially curative surgery may still be possible,” said Dr. Diane Simeone, Director of UC San Diego Moores Cancer Center and Founder and Chief Scientific Advisor of PRECEDE.
Where PRECEDE fits into this
Building an early detection pathway for pancreatic cancer requires something no single hospital or research group can produce alone: a large, well-characterized population of people at elevated risk, followed over time, with standardized imaging, blood samples, and clinical data collected the same way at every site.
That is what the PRECEDE Consortium was created to build. More than 65 academic medical centers across 12 countries now participate, and more than 12,000 participants have enrolled. Together they are working to define who is genuinely at high risk, determine how those individuals should be surveilled, and generate the biospecimen and data resources that early detection tests will be validated against.
Risk is often closer to home than people expect. A family history of pancreatic cancer warrants the same screening attention as a confirmed inherited genetic mutation, even without a positive test result. If a parent, sibling, or child has been diagnosed with pancreatic cancer, that is a conversation worth having with your physician, and it may make you eligible to enroll at a PRECEDE center.
Progress on every front
The right response to this week’s news is not to choose between better treatment and earlier detection. It is to insist on both.
Every advance in therapy raises the value of finding this cancer sooner, because the earlier a patient is diagnosed, the more of these advances they are eligible for and the more time those advances have to work. Moving the five-year survival rate from 13% to 50% will take progress on both fronts at once, and it will take sustained investment in the collaborative infrastructure that makes early detection science possible.
That is the work PRECEDE funds, and it is the work your support makes possible.
